Neuroendocrine Tumors

PHILADELPHIA — An AI model achieved high accuracy in detecting and distinguishing between cystic and solid pancreatic focal lesions during endoscopic ultrasound procedures, according to data presented at the ACG Annual Scientific Meeting.

Cabozantinib significantly improved PFS for patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors, according to phase 3 study results presented at ESMO Congress.

The FDA approved lutetium Lu 177 dotatate for the treatment of pediatric patients aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut and hindgut tumors.

In this video, Laleh Melstrom, MD, MS, discusses results from the NABNEC study, a randomized phase 2 study of nab-paclitaxel in combination with carboplatin as first-line treatment of gastrointestinal neuroendocrine carcinomas.

Adding radioligand therapy to first-line treatment of grade 2 or grade 3 gastroenteropancreatic neuroendocrine tumors conferred a significant reduction in risk for disease progression or death, results of a randomized study showed.

CHICAGO — Incidence of rectal neuroendocrine tumors has increased in younger adults compared with older adults over the past 20 years, mostly driven by a rise in younger women, according to research presented at Digestive Disease Week.

Only 30% of individuals with neuroendocrine tumors rank living longer as their single top priority in treating their cancer, according to a study conducted by researchers at City of Hope.

The FDA granted fast track designation to ITM-11 for treatment of gastroenteropancreatic neuroendocrine tumors.

Patients with neuroendocrine tumors are at greater risk for cancer-associated death compared with death due to other causes; however, mortality rates vary according to tumor site.